Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Withdrawn 1

Sponsor Class

NETWORK 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 1

Conditions

Lymphoma, Follicular 5Breast Neoplasms 5Neoplasm Metastasis 4Lymphoma, Non-Hodgkin 4Lymphoma 4Waldenstrom Macroglobulinemia 3Recurrence 3Pancreatic Neoplasms 3Neoplasms 3Melanoma 3Lymphoma, Large B-Cell, Diffuse 3Lymphoma, B-Cell, Marginal Zone 3Burkitt Lymphoma 3Multiple Myeloma 2Lymphoma, Mantle-Cell 2Leukemia 2Glioma 2Glioblastoma 2Colorectal Neoplasms 2Brain Neoplasms 2Virus Diseases 1Uterine Cervical Neoplasms 1Unspecified Adult Solid Tumor, Protocol Specific 1Squamous Cell Carcinoma of Head and Neck 1Skin Neoplasms 1Select Advanced Solid Tumors 1Pregnancy Related 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Pain 1Neuroectodermal Tumors 1

Interventions

Cyclophosphamide 65Peripheral Blood Stem Cell Transplantation 37fludarabine phosphate 36Doxorubicin 31Etoposide 30Vincristine 29Whole-Body Irradiation 28Rituximab 26Prednisone 26Brentuximab Vedotin 26Mycophenolic Acid 25Filgrastim 22Cyclosporine 22Methotrexate 20Busulfan 19Cytarabine 18Radiotherapy 17Antilymphocyte Serum 16Tacrolimus 15Melphalan 15Carboplatin 14Ifosfamide 13Bortezomib 13Methylprednisolone 12Gemcitabine 11Flow Cytometry 10Lenalidomide 9Dexamethasone 9romidepsin 8Vorinostat 8

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Lymphoma, Large-Cell, Anaplastic × Antibodies, Monoclonal × Clear all
NCT00310128 2016-02-03

Combination Chemotherapy Followed by Rituximab and Yttrium Y 90 Ibritumomab Tiuxetan in Treating Patients With Relapsed or Refractory AIDS-Related Non-Hodgkin's Lymphoma

AIDS Malignancy Consortium

Phase 2 Withdrawn
Lymphoid

Burkitt Lymphoma, Lymphoma, Follicular, Lymphoma, Non-Hodgkin, Lymphoma, Large-Cell, Immunoblastic, Lymphoma, Large B-Cell, Diffuse, Lymphoma, AIDS-Related, Lymphoma, Large-Cell, Anaplastic

Data powered by HemOnc (CC BY 4.0) Colophon âš¡